

11 August 2009

**Lifeline Scientific, Inc.**  
**(“Lifeline” or the “Company”)**

Block Listing Six Monthly Return

Name of Applicant:	Lifeline Scientific Inc.
Name of Scheme:	2004 – 2007 Bridge Warrants
Period of Return:	From 5 February 2009 to 7 August 2009
Balance of unallotted securities under the Scheme from previous announcement:	2,876,811
Number of Shares issued/allotted under the Scheme during the period:	914,908
Balance under the Scheme not yet issued/allotted at end of the period	1,961,903

Voting Rights and Share Capital

Lifeline has 16,707,240 common shares in issue and each share has the right to one vote. Therefore for the purposes of the FSA Disclosure and Transparency Rules the total number of voting rights in the Company is 16,707,240.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or change to their interest in, Lifeline Scientific, Inc. under the FSA’s Disclosure and Transparency Rules.

Update on outstanding 2004 Bridge Warrants and 2005 Bridge Warrants

As set out in the Admission Document the Company issued warrants in connection with its 2004 bridge financing (the “2004 Bridge Warrants”) and 2005 bridge financing (the “2005 Bridge Warrants”) (together the “Warrants”). The following Warrants are outstanding as at 7 August 2009.

2004 Bridge Warrants:

\$ Amount of Warrants	Issue Date	Expiration Date
\$31,400*	19/08/05	27/01/10
\$967,032	19/08/05	27/01/10
\$26,690*	19/08/05	31/07/09

2005 Bridge Warrants:

\$ Amount of Warrants	Issue Date	Expiration Date
\$500,000	19/08/05	02/03/11

11 August 2009

\$300,000	19/09/05	04/04/11
\$28,000*	19/09/05	26/05/11
\$10,000*	19/08/05	18/01/10
\$10,000*	19/08/05	14/01/10

\* Cashless exercise currently in process but not completed

In lieu of paying the Exercise Price upon exercise of the 2004 and 2005 Bridge Warrants, the Holder may elect to exercise those warrants on a cashless basis in which case the number of Common Shares issued to the warrant holder upon exercise of the warrant shall be reduced by the number of Common Shares with an aggregate Market Price as of the date of exercise equal to the aggregate exercise price for the total number of Common Shares which the Holder has elected to exercise pursuant to the warrant, as specified on the exercise notice.

**Enquiries:**

**Lifeline Scientific, Inc.** + 1 847 824 2420

David Kravitz, CEO

**Seymour Pierce** +44 (0)20 7107 8000

Mark Percy / Huaizheng Peng / Sarah Jacobs

**Financial Dynamics** +44 (0)20 7831 3113

Ben Brewerton